Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer

Fig. 2

Kaplan–Meier curves regarding overall survival and BRFS of pT3a prostate cancer patients stratified by SARIFA-status. A SARIFA positivity is not associated with a statistically significant decreased overall survival in pT3a PCa patients (p = 0.35). B Regarding BRFS, SARIFA positivity seems to be associated with a trend towards high recurrence rates (p = 0.11) – however, patient number with BRFS was limited in our analysis. BRFS: biochemical recurrence-free survival, SARIFA: Stroma-AReactive-Invasion-Front-Areas pT: depth of invasion

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us